Literature DB >> 21215831

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes.

Samuele Calabro1, Marco Tortoli, Barbara C Baudner, Alessandra Pacitto, Mario Cortese, Derek T O'Hagan, Ennio De Gregorio, Anja Seubert, Andreas Wack.   

Abstract

Vaccine adjuvants such as alum and the oil-in-water emulsion MF59 are used to enhance immune responses towards pure soluble antigens, but their mechanism of action is still largely unclear. Since most adjuvanted vaccines are administered intramuscularly, we studied immune responses in the mouse muscle and found that both adjuvants were potent inducers of chemokine production and promoted rapid recruitment of CD11b(+) cells. The earliest and most abundantly recruited cell type are neutrophils, followed by monocytes, eosinophils and later dendritic cells (DCs) and macrophages. Using fluorescent forms of MF59 and ovalbumin (OVA) antigen, we show that all recruited cell types take up both adjuvant and antigen to transport them to the draining lymph nodes (LNs). There, we found antigen-positive neutrophils and monocytes within hours of injection, later followed by B cells and DCs. Compared to alum, MF59-injection lead to a more prominent neutrophil recruitment and a more efficient antigen re-localization from the injection site to the LN. As antigen-transporting neutrophils were observed in draining LNs, we asked whether these cells play an essential role in MF59-mediated adjuvanticity. However, antibody-mediated neutrophil ablation left MF59-adjuvanticity unaltered. Further studies will reveal whether other single cell types are crucial or whether the different recruited cell populations are redundant with overlapping functions.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21215831     DOI: 10.1016/j.vaccine.2010.12.090

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  143 in total

Review 1.  Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): clues and pitfalls in the pediatric background.

Authors:  Susanna Esposito; Elisabetta Prada; Maria Vincenza Mastrolia; Giusyda Tarantino; Claudio Codecà; Donato Rigante
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.

Authors:  Imre Kacskovics; Judit Cervenak; Anna Erdei; Richard A Goldsby; John E Butler
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

3.  Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis.

Authors:  Weifeng Zhang; Lianyan Wang; Yuan Liu; Xiaoming Chen; Jiahui Li; Tingyuan Yang; Wenqi An; Xiaowei Ma; Ruowen Pan; Guanghui Ma
Journal:  Pharm Res       Date:  2013-10-30       Impact factor: 4.200

Review 4.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

5.  Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.

Authors:  Ryan F Russell; Jacqueline U McDonald; Laura Lambert; John S Tregoning
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

6.  How squalene GLAdly helps generate antigen-specific T cells via antigen-carrying neutrophils and IL-18.

Authors:  Justin D Kedl; Ross M Kedl
Journal:  Eur J Immunol       Date:  2015-02       Impact factor: 5.532

7.  A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.

Authors:  Melissa Santone; Susanna Aprea; Tom Y H Wu; Michael P Cooke; M Lamine Mbow; Nicholas M Valiante; James S Rush; Stephanie Dougan; Ana Avalos; Hidde Ploegh; Ennio De Gregorio; Cecilia Buonsanti; Ugo D'Oro
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses.

Authors:  Signe Tandrup Schmidt; Malene Aaby Neustrup; Stine Harloff-Helleberg; Karen Smith Korsholm; Thomas Rades; Peter Andersen; Dennis Christensen; Camilla Foged
Journal:  Pharm Res       Date:  2017-05-17       Impact factor: 4.200

9.  A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Authors:  Jesse H Erasmus; Amit P Khandhar; Jeff Guderian; Brian Granger; Jacob Archer; Michelle Archer; Emily Gage; Jasmine Fuerte-Stone; Elise Larson; Susan Lin; Ryan Kramer; Rhea N Coler; Christopher B Fox; Dan T Stinchcomb; Steven G Reed; Neal Van Hoeven
Journal:  Mol Ther       Date:  2018-08-02       Impact factor: 11.454

10.  Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.

Authors:  Xiaorui Chen; Bo Li; Jinfei Yu; Yue Zhang; Zujian Mo; Tiejun Gu; Wei Kong; Yong Zhang; Yongge Wu
Journal:  Med Microbiol Immunol       Date:  2019-02-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.